Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,097,141
  • Shares Outstanding, K 117,660
  • Annual Sales, $ 7,530 K
  • Annual Income, $ -526,240 K
  • EBIT $ -506 M
  • EBITDA $ -494 M
  • 60-Month Beta 0.78
  • Price/Sales 796.90
  • Price/Cash Flow N/A
  • Price/Book 49.56

Options Overview Details

View History
  • Implied Volatility 64.82% ( +1.42%)
  • Historical Volatility 30.88%
  • IV Percentile 47%
  • IV Rank 12.02%
  • IV High 291.99% on 12/19/23
  • IV Low 33.79% on 06/03/24
  • Put/Call Vol Ratio 0.95
  • Today's Volume 952
  • Volume Avg (30-Day) 861
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 92,814
  • Open Int (30-Day) 92,225

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.26
  • Number of Estimates 11
  • High Estimate -1.08
  • Low Estimate -1.46
  • Prior Year -1.35
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.53 +2.55%
on 10/31/24
56.99 -9.06%
on 10/07/24
-0.78 (-1.48%)
since 10/01/24
3-Month
50.53 +2.55%
on 10/31/24
58.68 -11.69%
on 08/29/24
-6.09 (-10.52%)
since 08/01/24
52-Week
30.68 +68.90%
on 11/28/23
110.25 -53.00%
on 01/08/24
+16.72 (+47.64%)
since 11/01/23

Most Recent Stories

More News
Cytokinetics to Announce Third Quarter Results on November 6, 2024

CYTK : 51.82 (+1.61%)
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

CYTK : 51.82 (+1.61%)
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTK : 51.82 (+1.61%)
Analysts Think There's Still Time to Get in on Edgewise, Up 332%

Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?

CYTK : 51.82 (+1.61%)
EWTX : 34.00 (+1.28%)
BMY : 54.32 (-2.60%)
Cytokinetics: Q2 Earnings Snapshot

Cytokinetics: Q2 Earnings Snapshot

CYTK : 51.82 (+1.61%)
Cytokinetics: Q1 Earnings Snapshot

Cytokinetics: Q1 Earnings Snapshot

CYTK : 51.82 (+1.61%)
2 Incredible Growth Stocks to Buy Right Now

These two biotech stocks could be big winners in the years ahead.

CYTK : 51.82 (+1.61%)
VKTX : 72.88 (+0.47%)
Cytokinetics: Q4 Earnings Snapshot

Cytokinetics: Q4 Earnings Snapshot

CYTK : 51.82 (+1.61%)
Markets Today: Stocks Slip on Hawkish Fed Comments

Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.30%, and March Nasdaq 100 E-Mini futures (NQH24 ) are down -0.19%. Stock index futures this morning are mildly lower as higher bond yields...

ESZ24 : 5,758.25s (+0.34%)
NQZ24 : 20,153.25s (+0.66%)
BA : 154.59 (+3.54%)
APD : 309.21 (-0.43%)
ZS : 182.59 (+1.00%)
MAT : 19.91 (-2.31%)
CYTK : 51.82 (+1.61%)
GWW : 1,105.07 (-0.38%)
CAT : 379.63 (+0.91%)
EL : 66.58 (-3.42%)
FDMT : 8.10 (+1.06%)
CTLT : 58.73 (+0.22%)
2 Biotechs That Could Get Bought Out in 2024

These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason.

CYTK : 51.82 (+1.61%)
BBIO : 25.48 (+8.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 53.80
2nd Resistance Point 53.09
1st Resistance Point 52.45
Last Price 51.82
1st Support Level 51.10
2nd Support Level 50.39
3rd Support Level 49.75

See More

52-Week High 110.25
Fibonacci 61.8% 79.85
Fibonacci 50% 70.46
Fibonacci 38.2% 61.08
Last Price 51.82
52-Week Low 30.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar